Unilateral inactivation of dopamine receptors after intrastriatal injection of N-ethoxy-carbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ): a novel rotational model to investigate dopamine receptor interactions.
The interaction between D1 and D2 dopamine (DA) receptors was investigated in a novel rotational model. Rats were unilaterally injected into the striatum with the irreversible DA receptor blocker N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ). This treatment induced a marked decrease in the density of D1 (-48%) and D2 (-45%) DA receptors available for binding to 3H-SCH 23390 and 3H-spiperone, respectively. Under these experimental conditions, the effect of DA receptor agonists were predominant on the intact side and resulted in rotations ipsilateral to the injected side. The effects of different agonists and antagonists for D1 and D2 DA receptors were evaluated 24 hr after EEDQ administration. The D2 agonist LY 171555 induced ipsilateral rotations in a dose-dependent manner (0.1-10.0 mg/kg, IP) in rats treated intrastriatally with EEDQ. In contrast, the D1 agonist SKF 38393 (1-20 mg/kg, IP) was unable to elicit circling behavior per se. However, SKF 38393 increased the number of rotations caused by LY 171555. The circling behavior induced by LY 171555 was blocked by the D2 antagonists (-)sulpiride and raclopride and by the D1 antagonist SCH 23390. Moreover, the inhibition of circling behavior induced by SCH 23390 was reversed by SKF 38393 in a dose-dependent manner. LY 171555 (1 mg/kg, IP) was unable to induce rotations in EEDQ-treated rats following DA depletion by alpha-methyl-p-tyrosine, whilst the combined administration of LY 171555 (1 mg/kg, IP) and SKF 38393 (10 mg/kg, IP) elicited intense circling behavior in DA depleted rats.(ABSTRACT TRUNCATED AT 250 WORDS)
Giorgi
O
O
Department of Experimental Biology, University of Cagliari, Italy.
Biggio
G
G
D015102:3,4-Dihydroxyphenylacetic Acid / Q000032:analysis; D000818:Animals; D001923:Brain Chemistry / Q000187:drug effects; D004298:Dopamine / Q000032:analysis; D015259:Dopamine Agents / Q000494:pharmacology*; D018492:Dopamine Antagonists; D004347:Drug Interactions; D008297:Male; D008781:Methyltyrosines / Q000494:pharmacology; D009043:Motor Activity / Q000187:drug effects* / Q000502:physiology; D011804:Quinolines / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D011954:Receptors, Dopamine / Q000032:analysis / Q000187:drug effects / Q000502:physiology*; D017981:Receptors, Neurotransmitter / Q000032:analysis / Q000187:drug effects; D016037:Single-Blind Method; D019805:alpha-Methyltyrosine
D015259:Dopamine Agents; D018492:Dopamine Antagonists; D008781:Methyltyrosines; D011804:Quinolines; D011954:Receptors, Dopamine; D017981:Receptors, Neurotransmitter; D015102:3,4-Dihydroxyphenylacetic Acid; C000470:EEDQ; D019805:alpha-Methyltyrosine; D004298:Dopamine